The well‐established molecular pathogenesis of chronic myelogenous leukemia (CML) and
its consequences for laboratory testing and clinical management illustrate a classic …

Imatinib was the first BCR‐ABL1 tyrosine kinase inhibitor (TKI) developed for the treatment
of patients with chronic myeloid leukemia (CML); subsequently, the introduction of more …

Since their introduction in 2001, tyrosine kinase inhibitors (TKIs) targeting BCR-ABL have
become the standard therapy for chronic myeloid leukaemia (CML). While allogeneic …

Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm, characterized by the
unrestrained expansion of pluripotent hematopoietic stem cells. CML was the first …

The role of molecular monitoring for patients with chronic myeloid leukemia (CML) is
multifaceted. Milestone measurements up to 18 months of first-line imatinib therapy are …

Chronic myeloid leukemia (CML) results from expression of the constitutive tyrosine kinase
activity of the Bcr-Abl oncoprotein. Imatinib, a tyrosine kinase inhibitor (TKI), is highly …

DATA SOURCES: Current literature. DATA SYNTHESIS: Chronic myelocytic leukemia
(CML) was initially described in 1845 and is considered one of the first leukemias …

Molecular monitoring of BCR–ABL transcript levels by real-time quantitative PCR is
increasingly used to assess treatment response in patients with chronic myeloid leukaemia …

Molecular monitoring of BCR-ABL1 transcripts for patients with chronic myeloid leukemia
(CML) is now used to assess response to tyrosine kinase inhibitors (TKIs), including …

The introduction of BCR-ABL1 tyrosine kinase inhibitors (TKIs) for treatment of chronic
myelogenous leukemia in chronic phase (CML-CP) has revolutionized therapy, altering the …